Merck & Company (NYSE: MRK) — Perfil da empresa, notícias e dados financeiros
Merck is a global pharmaceuticals company focused on innovative health solutions like medicines and vaccines.

Merck & Company
Merck & Company is a global healthcare enterprise that discovers, develops, manufactures, and markets biopharmaceutical prescription medicines, vaccines, biological therapies, and animal health products. The company operates through two main business segments: Pharmaceutical and Animal Health. Its pharmaceutical portfolio includes treatments across oncology, infectious diseases, cardiometabolic disorders, immunology, neuroscience, and respiratory conditions. Additionally, the organization develops and supplies vaccines for pediatric, adolescent, and adult populations, alongside veterinary medicines and health management products for livestock and companion animals worldwide.
Resumo
Operações
Produtos e/ou serviços de Merck & Company
- Oncology Therapeutics: Monoclonal antibodies and immunotherapies designed for cancer treatments, targeting programmatic cell death proteins across multiple solid tumor types, hematologic malignancies, and early-stage disease settings across international markets.
- Vaccines Portfolio: Human vaccines covering pediatric, adolescent, and adult immunizations for human papillomavirus, pneumococcal disease, rotavirus, measles, mumps, rubella, and varicella distributed to global health programs and clinical networks.
- Cardiometabolic and Respiratory Medicines: Pharmaceutical treatments targeting pulmonary arterial hypertension, type 2 diabetes, hypercholesterolemia, and chronic heart failure administered through oral formulations and specialized therapies across healthcare systems worldwide.
- Infectious Disease Treatments: Antiviral and antibacterial formulations providing therapeutic interventions for human immunodeficiency virus infections, severe fungal infections, cytomegalovirus in transplant recipients, and hospital-acquired bacterial infections.
- Immunology and Neuroscience Products: Targeted pharmaceutical biologicals and small molecule drugs engineered to manage autoimmune conditions, chronic inflammatory disorders, neurodegenerative conditions, and central nervous system disorders worldwide.
- Animal Health Solutions: Veterinary pharmaceuticals, biological products, vaccines, and digital livestock intelligence services for livestock, poultry, aquaculture, and companion animals distributed to veterinarians, producers, and pet owners globally.
equipe executiva do Merck & Company
- Robert M. DavisChairman, President & CEO
- Caroline A. LitchfieldExecutive VP & CFO
- Jennifer L. ZacharyExecutive VP & General Counsel
- Dean Y. LiExecutive VP & President of Merck Research Laboratories
- Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller
- Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Peter DannenbaumVice President of Investor Relations
- Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications
- Betty D. LarsonExecutive VP & Chief Human Resources Officer
- Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health
Últimas notícias sobre a Merck & Company
Merck gains EU backing after 26% risk reduction
United StatesMerck gains EU backing for 24-month RSV use
United StatesMerck lifts 2026 profit outlook to €6.4 billion
United StatesMerck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
United StatesEU approves Merck’s KEYTRUDA-Padcev bladder cancer regimen
United StatesMerck agrees to $1.3 billion Silence acquisition
United States
Comunicados recentes
O que a Merck & Company (MRK) comunicou ao mercado, do mais recente para o mais antigo.
Histórico de dividendos
Dividendos por ação pagos pela Merck & Company, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $2.5500 |
| FY2025 | — | — | — | $3.2800 |
| FY2024 | — | — | — | $3.1200 |
| FY2023 | — | — | — | $2.9600 |
| FY2022 | — | — | — | $2.8000 |
Principais indicadores financeiros
Resultados divulgados pela Merck & Company, em USD.
- Cap. de mercado
- 364,3 bi
- Receita (TTM)
- 67,4 bi
- P/L
- 147.8
- LPA (diluído, TTM)
- 1.0
- Dividend yield
- 2.3%
- Margem de lucro
- 3.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 64,9 bi | 23,5 bi | 18,3 bi | |
| 64,2 bi | 20,2 bi | 17,1 bi | |
| 60,1 bi | 3 bi | 365 mi | |
| 59,3 bi | 18,3 bi | 14,5 bi |